# Refractory Chronic Cough Improvement Via NAL ER (RIVER)

> **NCT05962151** · PHASE2 · COMPLETED · sponsor: **Trevi Therapeutics** · enrollment: 66 (actual)

## Conditions studied

- Refractory Chronic Cough

## Interventions

- **DRUG:** NAL ER
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05962151
- **Lead sponsor:** Trevi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-30
- **Primary completion:** 2025-01-06
- **Final completion:** 2025-01-06
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05962151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05962151, "Refractory Chronic Cough Improvement Via NAL ER (RIVER)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05962151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*